The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients

Background: This report describes the study design and baseline characteristics of patients with Stargardt disease (STGD1) enrolled in the STArgardt Remofuscin Treatment Trial (STARTT). Methods: In total, 87 patients with genetically confirmed STGD1 were randomized in a double-masked, placebo-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhooge, Patty P.A., Möller, Philipp T., Boon, Camiel J.F., Lotery, Andrew J., Herrmann, Philipp, Battaglia Parodi, Maurizio, Klein, Wolfgang, Fsadni, Mario G., Wheeler-Schilling, Thomas H., Jungmann, Oliver, Müller, Hans, Holz, Frank G., Schmitz-Valckenberg, Steffen, Peters, Tobias M., Stingl, Katarina, Hoyng, Carel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445898/
https://www.ncbi.nlm.nih.gov/pubmed/37645124
http://dx.doi.org/10.12688/openreseurope.13872.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445898/
https://www.ncbi.nlm.nih.gov/pubmed/37645124
http://dx.doi.org/10.12688/openreseurope.13872.3

Ejemplares similares